<meta http-equiv="Content-Type" content="text/html;charset=utf-8" /><!DOCTYPE doctype html>
<html class="Unknown 0_0 Unknown Unknown titanDisplay" id="htmlTag" xmlns="http://www.w3.org/1999/xhtml">
 <head>
  <link href="/ClientCss/style_eperc.css" rel="stylesheet" type="text/css"/>
  <meta content="Titan CMS" name="creator"/>
  <title id="pageTitle">
   #  002 Converting to/from Transdermal Fentanyl, 2nd ed
  </title>
  <meta content="70475" name="DocID">
   <meta content="#  002 Converting to/from Transdermal Fentanyl, 2nd ed" name="Title">
    <meta content="#2 Converting to/from Transdermal Fentanyl, 2nd ed, medical knowledge, opioids, pain" name="Keywords">
     <meta content="" name="Description">
      <meta content="" name="Abstract">
       <link href="/display/WhatsNew.rss" rel="alternate+rss" title="RSS" type="application/rss+xml"/>
       <script src="/Scripts/titanscripts.js" type="text/javascript">
       </script>
       <script src="/Scripts/Banner.js" type="text/javascript">
       </script>
       <script src="http://www.google.com/recaptcha/api/js/recaptcha_ajax.js" type="text/javascript">
       </script>
       <script src="/commonScripts/mcwCommon.js" type="text/javascript">
       </script>
       <script type="text/javascript">
        var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");
document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));
       </script>
       <script type="text/javascript">
        try {
var pageTracker = _gat._getTracker("UA-11124256-1");
pageTracker._trackPageview();
} catch(err) {}
       </script>
      </meta>
     </meta>
    </meta>
   </meta>
  </meta>
 </head>
 <body class="titanBody" id="bodyTag" onclick="if (window['TitanClickHandler']) TitanClickHandler(this, event)" onload="TitanLoad();">
  <form action="/EPERC/FastFactsIndex/ff_002.htm?" enctype="multipart/form-data" id="routerForm" method="post" name="routerForm">
   <input id="__VIEWSTATE" name="__VIEWSTATE" type="hidden" value="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"/>
   <script src="/ScriptResource.axd?d=xFDxeqDolrWHepB5BOa6WusqXFLn3wro2JYAUSW54WCZIM7tlRS9tbqUciiQ66IHFJNcNWN3CVU9VVXPPRcSENg7qOCQHN4cE4-dXQ8bxlvvzOwDdwbXgIu1gG27qPOQ1CQrIgFe_q5BlrAijrvDUgIWykSGToLqgYeMH1AtHUs1&amp;t=ffffffff940d030f" type="text/javascript">
   </script>
   <script src="/display/components/Blocks/Commenting/Support/CommentingAjax.asmx/js" type="text/javascript">
   </script>
   <div id="mainBody">
    <!--/pageTopArea -->
    <div id="contentArea">
     <div id="contentContainer">
      <!--/toolContainer -->
      <div id="centerZone">
       <div id="titleBarContainer">
        <h1>
         #  002 Converting to/from Transdermal Fentanyl, 2nd ed
        </h1>
       </div>
       <!--/titleBarContainer -->
       <div blockinfo="Freeform CenterZone BlockID1" class="Freeform CenterZone BlockID1">
        <h4>
         <a href="./ff_002.htm" linktype="4" target="_blank">
          FAST FACTS AND CONCEPTS #002 PDF
         </a>
        </h4>
        <p>
         <br/>
         <b>
          Author(s):
         </b>
         David E Weissman MD
        </p>
        <p>
         <b>
          Quick—
         </b>
         what dose of the transdermal fentanyl patch (Duragesic
         <sup>
          TM
         </sup>
         ) is equianalgesic to a 3 mg/hr morphine continuous infusion? Conversions to and from fentanyl transdermal are notoriously tricky, requiring knowledge of the published conversion data, general opioid pharmacology, and a generous dose of common sense. See also Fast Fact #36 on opioid dose conversions.
        </p>
        <p>
         <b>
          Step 1:
         </b>
         Calculate the 24 hr morphine dose: 3 mg/hr x 24 hrs = 72 mg IV morphine/24 hrs.
        </p>
        <p>
         <b>
          Step 2:
         </b>
         Convert the IV dose to the equianalgesic oral morphine dose using a ratio of:
         <br/>
         1 mg IV = 3 mg oral. Thus, 72 mg IV = 216 mg po/24 hours.
        </p>
        <p>
         <b>
          Step 3:
         </b>
         Convert the oral morphine dose to transdermal fentanyl. There are two methods:
        </p>
        <ul>
         <li>
          Method 1 – Standard Table. Look up fentanyl transdermal in the PDR and find the morphine conversion table. It says that 135-224 mg of morphine per 24 hours = 50 mcg/hr patch. Note: this range of morphine is very broad which may result in significant under dosing.
         </li>
         <li>
          Method 2 - Alternate Formula. In 2000, Brietbart, et al published an alternative method, based on the results of a multi-center trial by Donner, et al, that relied on a fixed dose conversion ratio to calculate the fentanyl transdermal dose. Brietbart recommended the ratio of:
         </li>
        </ul>
        <p style="margin-left: 80px">
         o 2 mg oral morphine/24 hr = 1 mcg/hr of transdermal fentanyl—rounded to the nearest patch size. In the case example above, 216 mg of oral morphine per day is approximately equianalgesic to the 100 mcg/hr fentanyl patch.
        </p>
        <p>
         <b>
          Note:
         </b>
         using this formula, 25 mcg/hr of transdermal fentanyl is roughly equivalent to 50 mg oral morphine/24 hours. This dose may be excessive when used in an opioid naïve patient, particularly the elderly.
        </p>
        <p>
         <b>
          Key Considerations
         </b>
        </p>
        <ol>
         <li>
          All equianalgesic ratios/formulas are approximations; clinical judgment is needed when making dose or drug conversions.
         </li>
         <li>
          The risk of sedation/respiratory depression with transdermal fentanyl is probably increased in the elderly or patients with liver and renal impairment due to its long half-life, thus, choose the lower end of the dosing spectrum.
         </li>
         <li>
          When in doubt, go low and slow, using prn breakthrough doses generously while finding the optimal dosage of a long-acting drug.
         </li>
        </ol>
        <p>
         <b>
          Other teaching points about Duragesic:
         </b>
        </p>
        <ul>
         <li>
          Start at the lowest dose, 12 mcg/hr, in an opioid naïve patient; there is no maximum dose.
         </li>
         <li>
          Therapeutic blood levels are not reached for 13-24 hours after patch application and drug will be continue to be released into the blood for at least 24 hours after patch removal.
         </li>
         <li>
          Opioid withdrawal symptoms can occur during dose conversions—care must be taken to avoid this by use of breakthrough opioids.
         </li>
         <li>
          Some patients will need to have their patches changed every 48 hours.
         </li>
         <li>
          The recommended upward dose titration interval is no more frequently than every 72 hours.
         </li>
         <li>
          Place patches on non-irradiated, hairless skin.
         </li>
         <li>
          Direct heat applied over the patch can increase drug absorption with increased toxic effects.
         </li>
         <li>
          There are no data that cachectic patients have reduced efficacy due to loss of subcutaneous fat
         </li>
        </ul>
        <p>
         <b>
          References
         </b>
        </p>
        <ol>
         <li>
          Physicians Desk Reference. Available at http://pdr.net.
         </li>
         <li>
          Donner B, et al. Direct conversion from oral morphine to transdermal fentanyl. Pain. 1996; 64:527-534.
         </li>
         <li>
          Payne R, et al. QOL and cancer pain: satisfaction and side effects with Transdermal fentanyl versus oral morphine. J Clinical Oncology. 1998:16:1588-1593.
         </li>
         <li>
          Breitbart W. An alternative algorithm for dosing transdermal fentanyl for cancer-related pain. Oncology. 2000; 14:695-702.
         </li>
         <li>
          Gourlay GK. Treatment of cancer pain with transdermal fentanyl. The Lancet Oncology. 2001; 2:165-172.
         </li>
        </ol>
        <p>
         <b>
          Fast Facts and Concepts
         </b>
         are edited by Drew A. Rosielle MD, Palliative Care Center, Medical College of Wisconsin. For more information write to:
         <a href="mailto:www.drosiell@mcw.edu?subject=EPERC%20Fast%20Facts%20and%20Concepts" linktype="5" target="_self">
          drosiell@mcw.edu
         </a>
         . More information, as well as the complete set of Fast Facts, are available at EPERC:
         <a href="http://www.eperc.mcw.edu" linktype="3" target="_blank">
          www.eperc.mcw.edu
         </a>
         .
        </p>
        <p>
         <b>
          Version History:
         </b>
         This Fast Fact was originally edited by David E Weissman MD. 2nd Edition published July 2005. Current version re-copy-edited March 2009; information about the lowest patch dose added.
        </p>
        
        <p>
         <b>
          Disclaimer:
         </b>
         Fast Facts and Concepts provide educational information. This information is not medical advice. Health care providers should exercise their own independent clinical judgment. Some Fast Facts cite the use of a product in a dosage, for an indication, or in a manner other than that recommended in the product labeling. Accordingly, the official prescribing information should be consulted before any such product is used.
        </p>
        <p>
         <b>
          ACGME Competencies:
         </b>
         Medical Knowledge
        </p>
        <p>
         <b>
          Keyword(s):
         </b>
         Pain, Opioids
        </p>
       </div>
      </div>
      <!--/centerZone -->
      <div id="rightZone">
      </div>
      <!--/rightZone -->
     </div>
     <!--/contentContainer -->
    </div>
    <!-- /contentArea -->
    <!--/bottomContainer -->
   </div>
   <!--/mainBody -->
   <input air="flowplayer.controls-air-3.2.12.swf" basedir="/display/components/Blocks/Freeform_CK/ckeditor/plugins/titanflowplayer/" id="flowPlayerSettings" js="flowplayer-3.2.11.min.js" modern="flowplayer.controls-3.2.12.swf" pseudo="flowplayer.pseudostreaming-3.2.9.swf" swf="flowplayer-3.2.12.swf" tube="flowplayer.controls-tube-3.2.12.swf" type="hidden"/>
  </form>
 </body>
</html>
